RecruitingNCT06830044
Milsaperidone added to medication for major depression
About this title
Read the official source — NCT06830044This study evaluates the safety and effectiveness of Milsaperidone for people with depression.
Medication studyAges 18–65Multiple countries
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of Milsaperidone for people with depression.
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- Phoenix and 52 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: March 3, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 500
- Sponsor
- Vanda Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Bulgaria, Czechia, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06830044
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Milsaperidone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Phoenix, United States · Little Rock, United States · Garden Grove, United States
42 more locations
- Orange, United States
- Redlands, United States
- San Jose, United States
- Walnut Creek, United States
- Colorado Springs, United States
- Fort Myers, United States
- Miami, United States
- Tampa, United States
- Snellville, United States
- Chicago, United States
- Carmel, United States
- Boston, United States
- Saint Charles, United States
- Las Vegas, United States
- New York, United States
- Staten Island, United States
- Charlotte, United States
- Cincinnati, United States
- Media, United States
- Houston, United States
- Plano, United States
- Richardson, United States
- Witchita Falls, United States
- Bellevue, United States
- Kardzhali, Bulgaria
- Pleven, Bulgaria
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Targovishte, Bulgaria
- Varna, Bulgaria
- Vratsa, Bulgaria
- Brno, Czechia
- Pilsen, Czechia
- Poruba, Czechia
- Prague, Czechia
- Bialystok, Poland
- Bydgoszcz, Poland
- Gdansk, Poland
- Katowice, Poland
- Suchy Las, Poland
- Torun, Poland
- Czechia
Interested in joining this study?
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of Milsaperidone for people with depression.
Who is behind this study?
The study sponsor is Vanda Pharmaceuticals.
Does this study involve medication?
Yes. The study involves medication, including Milsaperidone and Placebo.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
